Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).

Barre T, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B.

Addiction. 2019 Oct 8. doi: 10.1111/add.14820. [Epub ahead of print]

PMID:
31595554
2.

Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers' perspective using a mixed methods approach.

Djaogol T, Coste M, Marcellin F, Jaquet A, Chabrol F, Giles-Vernick T, Diallo A, Carrieri MP, Boyer S; ANRS 12356 AmBASS Study Group.

BMC Health Serv Res. 2019 Sep 4;19(1):627. doi: 10.1186/s12913-019-4416-3.

3.

Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).

Barré T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas Rojas T, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K, Chas J, Zaegel O, Chaix ML, Miailhes P, Serfaty L, Marcellin F, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914. [Epub ahead of print]

PMID:
31466125
4.

Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356).

Coste M, De Sèze M, Diallo A, Carrieri MP, Marcellin F, Boyer S; ANRS 12356 AmBASS Study Group.

BMJ Open. 2019 Jul 17;9(7):e030211. doi: 10.1136/bmjopen-2019-030211.

5.

HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort).

Santos ME, Protopopescu C, Sogni P, Yaya I, Piroth L, Bailly F, Marcellin F, Esterle L, Wittkop L, Rosenthal E, Morlat P, Roux P, de Araujo WN, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

AIDS Behav. 2019 Jul 8. doi: 10.1007/s10461-019-02585-7. [Epub ahead of print]

PMID:
31286317
6.

Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.

Rojas Rojas T, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B, Marcellin F.

Int J Drug Policy. 2019 Oct;72:61-68. doi: 10.1016/j.drugpo.2019.05.013. Epub 2019 May 22.

PMID:
31129024
7.

Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).

Costa M, Rojas Rojas T, Lacoste D, Villes V, Aumaitre H, Protopopescu C, Yaya I, Wittkop L, Krause J, Salmon-Céron D, Marcellin F, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]

PMID:
31094856
8.

Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs.

Chabrol F, Noah Noah D, Tchoumi EP, Vidal L, Kuaban C, Carrieri MP, Boyer S; EVOLCam group.

BMJ Open. 2019 Mar 20;9(3):e025415. doi: 10.1136/bmjopen-2018-025415.

9.

Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study.

Kankou JM, Bouchaud O, Lele N, Guiguet M, Spire B, Carrieri MP, Abgrall S; ANRS-VIHVO Study Group.

J Immigr Minor Health. 2019 Feb 22. doi: 10.1007/s10903-019-00864-y. [Epub ahead of print]

10.

Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.

Auriacombe M, Roux P, Briand Madrid L, Kirchherr S, Kervran C, Chauvin C, Gutowski M, Denis C, Carrieri MP, Lalanne L, Jauffret-Roustide M; Cosinus study group.

BMJ Open. 2019 Feb 21;9(2):e023683. doi: 10.1136/bmjopen-2018-023683.

11.

Clinical Features and Complications of Coxiella burnetii Infections From the French National Reference Center for Q Fever.

Melenotte C, Protopopescu C, Million M, Edouard S, Carrieri MP, Eldin C, Angelakis E, Djossou F, Bardin N, Fournier PE, Mège JL, Raoult D.

JAMA Netw Open. 2018 Aug 3;1(4):e181580. doi: 10.1001/jamanetworkopen.2018.1580.

12.

No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).

Marcellin F, Protopopescu C, Wittkop L, Salmon-Ceron D, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):274-276. doi: 10.1097/MEG.0000000000001301. No abstract available.

PMID:
30575641
13.

Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort).

Marcellin F, Costa M, Wittkop L, Protopopescu C, Esterle L, Salmon-Ceron D, Sogni P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Am J Gastroenterol. 2018 Nov;113(11):1729-1732. doi: 10.1038/s41395-018-0270-x. No abstract available.

PMID:
30333544
14.

Access to care for people with alcohol use disorder in France: a mixed-method cross-sectional study protocol (ASIA).

Costa M, Marcellin F, Coste M, Barré T, Nordmann S, Mora M, Maradan G, Tanti M, Cutarella C, Casanova D, Levy-Bellaiche S, Polomeni P, Simon N, Roux P, Carrieri MP.

BMJ Open. 2018 Sep 28;8(9):e024669. doi: 10.1136/bmjopen-2018-024669.

15.

Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.

Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Jul 5;13(7):e0199874. doi: 10.1371/journal.pone.0199874. eCollection 2018.

16.

Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort).

Yaya I, Marcellin F, Costa M, Morlat P, Protopopescu C, Pialoux G, Santos ME, Wittkop L, Esterle L, Gervais A, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13-HEPAVIH Cohort Study Group.

Nutrients. 2018 May 31;10(6). pii: E705. doi: 10.3390/nu10060705.

17.

Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research.

Marcellin F, Fontaine H, Serfaty L, Sogni P, Carrieri MP.

Expert Rev Anti Infect Ther. 2018 May;16(5):377-380. doi: 10.1080/14787210.2018.1473764. Epub 2018 May 8. No abstract available.

PMID:
29737223
18.

Reply to: "Coffee consumption and decreased all-cause mortality - What is the true estimate of effect?"

Protopopescu C, Marcellin F, Salmon-Ceron D, Carrieri MP.

J Hepatol. 2018 May;68(5):1106. doi: 10.1016/j.jhep.2018.01.032. Epub 2018 Feb 8. No abstract available.

PMID:
29427730
19.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.

PMID:
29214737
20.

The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Wittkop L, Lacombe K, Esterle L, Sogni P, Salmon-Ceron D; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2018 Apr;68(4):845-847. doi: 10.1016/j.jhep.2017.10.025. Epub 2017 Nov 2. No abstract available.

PMID:
29104123
21.

Gender, Alcohol Use, and Fibrosis in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Individuals.

Yaya I, Costa M, Marcellin F, Miailhes P, Wittkop L, Salmon-Ceron D, Carrieri MP; Agence Nationale de Recherches sur le Sida et les Hépatites virales B et C (ANRS) CO13 HEPAVIH (hepatitis + VIH [= HIV in French]) Study Group.

Clin Infect Dis. 2018 Mar 5;66(6):983-984. doi: 10.1093/cid/cix927. No abstract available.

PMID:
29088334
22.

Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.

Marcellin F, Morlat P, Wittkop L, Salmon-Ceron D, Carrieri MP.

J Viral Hepat. 2018 Mar;25(3):314-315. doi: 10.1111/jvh.12811. Epub 2017 Nov 20. No abstract available.

PMID:
29080244
23.

Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Rosellini S, Wittkop L, Esterle L, Zucman D, Raffi F, Rosenthal E, Poizot-Martin I, Salmon-Ceron D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2017 Dec;67(6):1157-1167. doi: 10.1016/j.jhep.2017.08.005. Epub 2017 Sep 21.

PMID:
28942916
24.

Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort).

Yaya I, Roux P, Marcellin F, Salmon-Ceron D, Carrieri MP.

Dig Dis Sci. 2017 Oct;62(10):2943-2944. doi: 10.1007/s10620-017-4703-y. Epub 2017 Aug 5. No abstract available.

PMID:
28780609
25.

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort.

Knight R, Roux P, Vilotitch A, Marcellin F, Rosenthal E, Esterle L, Boué F, Rey D, Piroth L, Dominguez S, Sogni P, Salmon-Ceron D, Spire B, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Addiction. 2017 Sep;112(9):1669-1679. doi: 10.1111/add.13851. Epub 2017 Jun 6.

PMID:
28430385
26.

Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).

Marcellin F, Protopopescu C, Esterle L, Wittkop L, Piroth L, Aumaitre H, Bouchaud O, Goujard C, Vittecoq D, Dabis F, Salmon-Ceron D, Spire B, Roux P, Carrieri MP; ANRS CO13-HEPAVIH Study Group.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):786-791. doi: 10.1097/MEG.0000000000000883.

PMID:
28418984
27.

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).

Carrieri MP, Protopopescu C, Younossi Z, Vilotitch A, Fontaine H, Petrov-Sanchez V, Marcellin F, Carrat F, Hézode C, Bourlière M; CUPIC Study Group.

Patient. 2017 Oct;10(5):605-614. doi: 10.1007/s40271-017-0232-1.

PMID:
28353221
28.

Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey).

Carrieri MP, Marcellin F, Fressard L, Préau M, Sagaon-Teyssier L, Suzan-Monti M, Guagliardo V, Mora M, Roux P, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

PLoS One. 2017 Feb 13;12(2):e0171645. doi: 10.1371/journal.pone.0171645. eCollection 2017.

29.

Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues.

Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP.

Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):259-268. doi: 10.1080/17474124.2017.1285227. Epub 2017 Jan 31. Review.

PMID:
28116926
30.

Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients: The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort.

Protopopescu C, Carrieri MP, Raffi F, Picard O, Hardel L, Piroth L, Jadand C, Pierret J, Spire B, Leport C; ANRS CO8 APROCO-COPILOTE Study Group.

J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):293-297. doi: 10.1097/QAI.0000000000001249.

PMID:
27861235
31.

Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).

Fontaine H, Maynard M, Bouix C, Carrieri MP, Botta-Fridlund D, D'Alteroche L, Conti F, Pageaux GP, Leroy V, Métivier S, Anty R, Durand F, Canva V, Vilotitch A, Lebray P, Alric L, Duvoux C, Petrov-Sanchez V, Beaulieux F, Wellems C, Paul C, Roque-Afonso AM, Roche B, Pradat P, Samuel D, Duclos-Vallée JC; BOCEPRETRANSPLANT study group.

Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):56-65. doi: 10.1016/j.clinre.2016.06.006. Epub 2016 Aug 20.

PMID:
27554134
32.

Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].

Michel L, Lions C, Winnock M, Lang JP, Loko MA, Rosenthal E, Marchou B, Valantin MA, Morlat P, Roux P, Sogni P, Spire B, Poizot-Martin I, Lacombe K, Lascoux-Combe C, Duvivier C, Neau D, Dabis F, Salmon-Ceron D, Carrieri MP; ANRS HEPAVIH CO13 study group.

HIV Med. 2016 Nov;17(10):758-765. doi: 10.1111/hiv.12382.

33.

Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).

Marcellin F, Protopopescu C, Poizot-Martin I, Miailhes P, Esterle L, Wittkop L, Spire B, Bocquier A, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group.

Eur J Gastroenterol Hepatol. 2016 Sep;28(9):1003-7. doi: 10.1097/MEG.0000000000000664.

PMID:
27177169
34.

Factors Associated with HIV Status Disclosure in HIV-Infected Sub-Saharan Migrants Living in France and Successfully Treated with Antiretroviral Therapy: Results from the ANRS-VIHVO Study.

Kankou JM, Bouchaud O, Lele N, Bourgeois D, Spire B, Carrieri MP, Abgrall S; ANRS-VIHVO Study Group.

J Immigr Minor Health. 2017 Aug;19(4):843-850. doi: 10.1007/s10903-016-0423-1.

PMID:
27125911
35.

From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals: self-reported symptoms as a warning signal for potential adverse events (ANRS HC26, ANRS HC27 trials).

Marcellin F, Fournier I, Carrieri MP, Poizot-Martin I, Cotte L; ANRS HC26 & ANRS HC27 Study Groups.

Eur J Gastroenterol Hepatol. 2016 Jun;28(6):733-4. doi: 10.1097/MEG.0000000000000612. No abstract available.

PMID:
27111390
36.

No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).

Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, Protopopescu C, Spire B, Salmon-Ceron D, Dabis F, Carrieri MP; HEPAVIH ANRS CO13 Study Group*.

Drug Alcohol Rev. 2017 Mar;36(2):227-238. doi: 10.1111/dar.12398. Epub 2016 Apr 13.

PMID:
27073179
37.

A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study).

Nordmann S, Lions C, Vilotitch A, Michel L, Mora M, Spire B, Maradan G, Morel A, Roux P, Carrieri MP; ANRS Methaville study group.

Psychopharmacology (Berl). 2016 Apr;233(7):1203-13. doi: 10.1007/s00213-016-4202-4. Epub 2016 Jan 12.

PMID:
26753792
38.

Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey).

Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836. No abstract available.

PMID:
26569181
39.

B-cell non-Hodgkin lymphoma linked to Coxiella burnetii.

Melenotte C, Million M, Audoly G, Gorse A, Dutronc H, Roland G, Dekel M, Moreno A, Cammilleri S, Carrieri MP, Protopopescu C, Ruminy P, Lepidi H, Nadel B, Mege JL, Xerri L, Raoult D.

Blood. 2016 Jan 7;127(1):113-21. doi: 10.1182/blood-2015-04-639617. Epub 2015 Oct 13.

PMID:
26463422
40.

Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study.

Mayet A, Lions C, Roux P, Mora M, Maradan G, Morel A, Michel L, Marimoutou C, Carrieri MP.

J Subst Abuse Treat. 2015 Nov;58:100-5. doi: 10.1016/j.jsat.2015.06.015. Epub 2015 Jul 3.

PMID:
26260134
41.

Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study.

Roux P, Le Gall JM, Debrus M, Protopopescu C, Ndiaye K, Demoulin B, Lions C, Haas A, Mora M, Spire B, Suzan-Monti M, Carrieri MP.

Addiction. 2016 Jan;111(1):94-106. doi: 10.1111/add.13089. Epub 2015 Sep 28.

PMID:
26234629
42.

Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.

Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, Peytavin G, Spire B, Delaporte E, Laurent C; Stratall ANRS 12110ESTHER Study Group.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):355-64. doi: 10.1097/QAI.0000000000000604.

PMID:
26181708
43.

The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.

Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourlière M.

Liver Int. 2016 Jan;36(1):42-8. doi: 10.1111/liv.12886. Epub 2015 Jun 24.

PMID:
26059860
44.

Securing opioid substitution treatment access and quality for people who inject drugs.

Carrieri MP, Sagaon-Teyssier L, Roux P.

AIDS. 2015 May 15;29(8):975-6. doi: 10.1097/QAD.0000000000000641. No abstract available.

PMID:
25909829
45.

Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.

Protopopescu C, Raffi F, Spire B, Hardel L, Michelet C, Cheneau C, Le Moing V, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group.

Antivir Ther. 2015;20(7):763-72. doi: 10.3851/IMP2960. Epub 2015 Apr 10.

46.

Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH).

Carrieri MP, Serfaty L, Vilotitch A, Winnock M, Poizot-Martin I, Loko MA, Lions C, Lascoux-Combe C, Roux P, Salmon-Ceron D, Spire B, Dabis F; ANRS CO13 HEPAVIH Study Group.

Clin Infect Dis. 2015 Jul 1;61(1):40-8. doi: 10.1093/cid/civ217. Epub 2015 Mar 16.

PMID:
25778750
47.

Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).

Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group.

Expert Rev Gastroenterol Hepatol. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914. Epub 2015 Feb 27.

PMID:
25723557
48.

Increasing access to opioid maintenance treatment: the role of primary care in France.

Roux P, Lions C, Carrieri MP.

Int J Drug Policy. 2015 Apr;26(4):434-5. doi: 10.1016/j.drugpo.2015.01.014. Epub 2015 Jan 19. No abstract available.

PMID:
25683137
49.

HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions.

Roux P, Sagaon-Teyssier L, Lions C, Fugon L, Verger P, Carrieri MP.

BMJ Open. 2014 Oct 19;4(10):e005694. doi: 10.1136/bmjopen-2014-005694.

50.

Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey).

Marcellin F, Lorente N, Demoulin B, Carrieri MP, Suzan-Monti M, Roux P, Lert F, Sagaon-Teyssier L, Dray-Spira R, Spire B; ANRS VESPA2 Study Group.

Sex Transm Infect. 2015 Feb;91(1):21-3. doi: 10.1136/sextrans-2014-051542. Epub 2014 Aug 5.

PMID:
25096920

Supplemental Content

Loading ...
Support Center